Nateglinid’ s virkning i monoterapi var mindre end metformins (fald i HbA1c (%) med 500 mg metformin 3 gange daglig i monoterapi: – 1, 23 [95% CI: – 1, 48; – 0, 99] og med nateglinid 120 mg 3 gange daglig i monoterapi: – 0, 90 [95% CI: – 1, 14; – 0, 66]).
Nateglinide efficacy was inferior to that of metformin in monotherapy (decrease in HbA1c (%) with metformin 500 mg three times daily monotherapy: – 1.23 [95% CI: – 1.48; – 0.99] and with nateglinide 120 mg three times daily monotherapy – 0.90 [95% CI: – 1.14; – 0.66]).